切换至 "中华医学电子期刊资源库"

中华结直肠疾病电子杂志 ›› 2021, Vol. 10 ›› Issue (03) : 266 -272. doi: 10.3877/cma.j.issn.2095-3224.2021.03.008

论著

结直肠癌中VASP表达及与转移关系研究
党运芝1, 于娇1, 赵淑红1, 金龙1, 任晓跃1, 王青1,()   
  1. 1. 710068 西安,陕西省人民医院放疗科
  • 收稿日期:2020-11-24 出版日期:2021-06-25
  • 通信作者: 王青
  • 基金资助:
    陕西省社会发展攻关计划项目(2009K12-01); 陕西省重点研发计划(2021SF-306)

The expression of VASP in colorectal cancer and its relationship with metastasis

Yunzhi Dang1, Jiao Yu1, Shuhong Zhao1, Long Jin1, Xiaoyue Ren1, Qing Wang1()   

  1. 1. Department of Radiation Oncology, Shaanxi Provincial People's Hospital, Xi'an 710068, China
  • Received:2020-11-24 Published:2021-06-25
  • Corresponding author: Qing Wang
引用本文:

党运芝, 于娇, 赵淑红, 金龙, 任晓跃, 王青. 结直肠癌中VASP表达及与转移关系研究[J/OL]. 中华结直肠疾病电子杂志, 2021, 10(03): 266-272.

Yunzhi Dang, Jiao Yu, Shuhong Zhao, Long Jin, Xiaoyue Ren, Qing Wang. The expression of VASP in colorectal cancer and its relationship with metastasis[J/OL]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2021, 10(03): 266-272.

目的

本研究旨在探讨VASP在结直肠癌中的表达,VASP与结直肠癌转移的关系。

方法

实时定量PCR及免疫组化方法分析VASP在结直肠癌组织中的表达量。通过体外Transwell实验及裸鼠体内尾静脉转移模型,分析VASP与结直肠癌转移的关系。

结果

VASP在结直肠癌中的表达较癌旁明显升高(χ2=82.1,P<0.001)。VASP与肿瘤大小、肿瘤分化、神经侵犯、淋巴结转移、远处转移、AJCC分期呈正相关。COX多因素分析表明VASP的表达是结直肠癌患者复发及死亡的独立预测因素之一。而体内外实验发现,过表达VASP可促进结直肠癌细胞的侵袭和转移。

结论

VASP在结直肠癌中表达升高与结直肠癌预后差呈正相关,过表达VASP可促进结直肠癌的转移,是结直肠癌治疗的潜在靶点。

Objective

We analyze the expression of VASP in CRC, and study the role of VASP in promoting CRC metastasis.

Methods

The expression of VASP was detected by Real-time PCR and immunohistochemistry in human CRC cohort. The effect of VASP-mediated invasion and metastasis were analyzed by Transwell assays and tail veins metastasis model both in vitro and in vivo.

Results

The expression levels of VASP were dramatically higher in CRC tissues than in adjacent nontumor tissues (χ2=82.1,P<0.001). Elevated expression of VASP was positively correlated with tumor size, tumor differentiation, nerve invasion, the lymph node metastasis, distant metastasis, higher American Joint Committee on Cancer (AJCC stage) and poor prognosis in human CRC. COX analysis indicated VASP expression was independent predictor for high recurrence rate and poor overall survival. Elevated expression of VASP promotes CRC metastasis both in vitro and in vivo.

Conclusion

VASP was overexpression and correlated with poor prognosis in CRC. Upregulated VASP can promote CRC metastasis and could be served as a potential treatment marker for CRC patients.

图1 VASP在结直肠癌中的表达。1A:实时定量PCR方法分析正常肠上皮组织、癌旁及CRC组织中VASP mRNA的表达水平;复发与未复发CRC患者VASP mRNA的表达;转移与未转移CRC患者VASP mRNA的表达;20对配对的正常肠上皮组织、原发CRC及转移CRC中VASP mRNA的表达。1B:IHC检测VASP在20例配对的癌旁,原发性CRC及远处转移CRC的表达情况。1C:IHC染色分析VASP在癌旁及CRC的蛋白表达情况及IHC评分情况。1D:Kaplan-Meier方法分析VASP的表达与复发及生存的关系。低倍镜图中bar值代表250 μm,高倍镜图中bar值为50 μm。*P<0.05
表1 结直肠患者中VASP的表达与临床参数的相关性
表2 VASP的表达是结直肠癌患者复发及死亡的独立预测因素
临床参数 复发时间 总体生存时间
HR(95% CI P HR(95% CI P
单因素分析

年龄(≤60 vs. >60)

0.937(0.666~1.317) 0.707 0.942(0.670~1.324) 0.729

性别(女vs.男)

0.881(0.627~1.238) 0.465 0.913(0.650~1.284) 0.603

肿瘤大小(≤5 cm vs.>5 cm)

1.304(0.921~1.845) 0.135 0.739(0.522~1.047) 0.089

肿瘤分化(高/中vs.差)

0.165(0.115~0.238) <0.001 0.156(0.108~0.225) <0.001

肿瘤浸润(Ⅰ~Ⅱ vs. Ⅲ)

0.290(0.20~0.422) <0.001 0.296(0.204~0.403) <0.001

脉管侵犯(无vs.有)

0.704(0.480~1.032) 0.072 0.671(0.46~0.98) 0.040

神经侵犯(无vs.有)

0.879(0.605~1.28) 0.50 0.837(0.58~1.21) 0.35

治疗方式(单纯手术vs.手术+放疗/化疗)

0.278(0.19~0.39) <0.001 0.273(0.18~0.36) <0.001

淋巴结转移(无vs.有)

0.0960(0.063~0.146) <0.001 0.096(0.064~0.146) <0.001

远处转移(无vs.有)

0.098(0.062~0.153) <0.001 0.101(0.065~0.156) <0.001

VASP表达(无vs.有)

0.252(0.176~0.360) <0.001 0.249 (0.177~0.3627) <0.001
多因素分析

肿瘤分化(好/中 vs.差)

0.857(0.532~1.381) 0.526 0.797(0.493~1.288) 0.354

肿瘤浸润(Ⅰ~Ⅱ vs. Ⅲ~Ⅳ)

0.558(0.278~1.119) 0.10 0.854(0.562~1.296) 0.457

淋巴结转移(无 vs. 有)

0.291(0.156~0.542) <0.001 0.266(0.142~0.498) <0.001

脉管侵犯(无 vs.有)

0.681(0.457~1.014) 0.058 0.689(0.463~1.025) 0.066

神经侵犯(无 vs.有)

1.317(0.877~1.979) 0.184 1.223(0.814~1.836) 0.333

治疗方式(单纯手术 vs.手术+放疗/化疗)

0.835(0.550~1.266) 0.395 0.854(0.562~1.296) 0.457

远处转移(无 vs. 有)

0.233(0.137~0.396) <0.001 0.261(0.157~0.435) <0.001

AJCC分期(Ⅰ~Ⅱ vs. Ⅲ)

0.525(0.314~0.877) 0.014 0.578(0.343~0.973) 0.039

VASP表达(阴性 vs. 阳性)

0.402(0.267~0.604) <0.001 0.476(0.316~0.715) <0.001
图2 VASP可促进结直肠癌细胞的侵袭和迁移。2A:VASP在正常肠上皮、结肠永生化细胞及10种CRC细胞系中的表达;2B:慢病毒转染后VASP在相应细胞中的表达;2C:Transwell实验分析SW480-VASP,SW620-shVASP与相应对照组细胞的侵袭和迁移能力
图3 VASP可促进结直肠癌细胞的肺转移。3A:生物发光成像显示各组裸鼠体内转移情况;3B:各组裸鼠尾静脉注射后0~9周活体成像的信号值;3C:各组裸鼠肺部代表性的HE图像;3D:各组裸鼠肺转移发生率;3E:各组裸鼠肺脏转移灶的数目;3F:各组裸鼠的总体生存。*P<0.05
1
Freddie B, Jacques F, Isabelle S, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
2
Fakih GM, Metastatic colorectal cancer: current state and future directions[J]. J Clin Oncol, 2015. 33(16): 1809-1824.
3
Jemal A, Siege R, Ward E, et al. Cancer statistics, 2008[J]. CA Cancer J Clin, 2008. 58(2): 71-96.
4
Punt CJ, Koopman M, Vermeulen L, et al. From tumour heterogeneity to advances in precision treatment of colorectal cancer[J]. Nat Rev Clin Oncol, 2017, 14(4): 235-246.
5
Shami K, Kevin CO, Nicole LE, et al. American cancer society colorectal cancer survivorship care guidelines[J]. CA Cancer J Clin, 2015, 65(6): 428-455.
6
Krause M, Erik WD, James EB, et al. Ena/VASP proteins: regulators of the actin cytoskeleton and cell migration[J]. Annu Rev Cell Dev Biol, 2003, 19: 541-564.
7
Dennis B, Antje KK, Joern K, et al. Molecular mechanism of Ena/VASP-mediated actin-filament elongation[J]. EMBO J, 2011, 30(3): 456-467.
8
Chen XJ, Anna JS, Raiko S, et al. Ena/VASP proteins cooperate with the WAVE complex to regulate the actin cytoskeleton[J]. Dev Cell, 2014, 30(5): 569-584.
9
Tu KS, Li JC, Liu CS, et al. Vasodilator-stimulated phosphoprotein promotes activation of hepatic stellate cells by regulating Rab11-dependent plasma membrane targeting of transforming growth factor beta receptors[J]. Hepatology, 2015, 61(1): 361-374.
10
Wang J, Zhang J, Wu J, et al. MicroRNA-610 inhibits the migration and invasion of gastric cancer cells by suppressing the expression of vasodilator-stimulated phosphoprotein[J]. Eur J Cancer, 2012, 48(12): 1904-1913.
11
Carmona G, Perera U, Gillett C, et al. Lamellipodin promotes invasive 3D cancer cell migration via regulated interactions with Ena/VASP and SCAR/WAVE[J]. Oncogene, 2016, 35(39): 5155-5169.
12
Liu ZK, Wang YF, Dou CW, et al. Hypoxia-induced up-regulation of VASP promotes invasiveness and metastasis of hepatocellular carcinoma[J]. Theranostics, 2018, 8(17): 4649-4663.
13
Li K, Zhang J, Tian Y, et al. The Wnt/β-catenin/VASP positive feedback loop drives cell proliferation and migration in breast cancer[J]. Oncogene, 2020, 39(11): 2258-2274.
14
Dang YZ, Chen J, Feng WB, et al. Interleukin 1β-mediated HOXC10 overexpression promotes hepatocellular carcinoma metastasis by upregulating PDPK1 and VASP[J]. Theranostics, 2020, 10(8): 3833-3848.
15
Huang F, Ma G, Zhou X, et al. Depletion of LAMP3 enhances PKA-mediated VASP phosphorylation to suppress invasion and metastasis in esophageal squamous cell carcinoma[J]. Cancer Lett, 2020, 479: 100-111.
16
田耀文, 霍婷婷, 王东旭, 等. 结直肠癌同时性肝外转移相关临床病理因素分析[J]. 中华肿瘤防治杂志, 2018, 25(2): 135-139.
17
Pitari GM, Cotzia P, Ali M, et al. Vasodilator-stimulated phosphoprotein biomarkers are associated with invasion and metastasis in colorectal cancer[J]. Biomark Cancer, 2018, 10: 1179299X18774551.
18
宋胜江, 孙利敏, 徐定银, 等. VASP在结肠癌组织中的表达及其对预后的影响[J]. 实用肿瘤杂志, 2016, 31(1): 48-52.
19
陈晨, 金旭, 翁稚颖, 等. PKG、PKA及VASP在人结直肠癌组织中的表达及临床意义[J]. 重庆医学, 2019, 48(10): 1669-1673.
[1] 周世振, 朱兴亚, 袁庆港, 刘理想, 王凯, 缪骥, 丁超, 汪灏, 管文贤. 吲哚菁绿荧光成像技术在腹腔镜直肠癌侧方淋巴结清扫中的应用效果分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 44-47.
[2] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[3] 徐逸男. 不同术式治疗梗阻性左半结直肠癌的疗效观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 72-75.
[4] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[5] 贺斌, 马晋峰. 胃癌脾门淋巴结转移危险因素[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 694-699.
[6] 林逸, 钟文龙, 李锴文, 何旺, 林天歆. 广东省医学会泌尿外科疑难病例多学科会诊(第15期)——转移性膀胱癌的综合治疗[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 648-652.
[7] 刘敏思, 李荣, 李媚. 基于GGT与Plt比值的模型在HBV相关肝细胞癌诊断中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 831-835.
[8] 陆镜明, 韩大为, 任耀星, 黄天笑, 向俊西, 张谞丰, 吕毅, 王傅民. 基于术前影像组学的肝内胆管细胞癌淋巴结转移预测的系统性分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 852-858.
[9] 张润锦, 阳盼, 林燕斯, 刘尊龙, 刘建平, 金小岩. EB病毒相关胆管癌伴多发转移一例及国内文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 865-869.
[10] 严虹霞, 王晓娟, 张毅勋. 2 型糖尿病对结直肠癌患者肿瘤标记物、临床病理及预后的影响[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 483-487.
[11] 赵磊, 刘文志, 林峰, 于剑, 孙铭骏, 崔佑刚, 张旭, 衣宇鹏, 于宝胜, 冯宁. 深部热疗在改善结直肠癌术后辅助化疗副反应及生活质量中的作用研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 488-493.
[12] 黄海洋, 邝永龙, 陈嘉胜. 基层医院结直肠肿瘤经自然腔道取标本手术30 例分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 510-518.
[13] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[14] 梁轩豪, 李小荣, 李亮, 林昌伟. 肠梗阻支架置入术联合新辅助化疗治疗结直肠癌急性肠梗阻的疗效及其预后的Meta 分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 472-482.
[15] 刘郁, 段绍斌, 丁志翔, 史志涛. miR-34a-5p 在结肠癌患者的表达及其与临床特征及预后的相关性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 485-490.
阅读次数
全文


摘要